The company's drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. Their technology enables them to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative “molecular glues” allow them to treat disease in entirely new ways by pursuing highly disease relevant targets that have long been considered undruggable or are inadequately addressed. Their initial focus on targeted protein degradation is driven by their desire to discover and develop groundbreaking new cancer medicines. Triana Biomedicines is headquartered in Waltham, Massachusetts, and has established internal laboratory work as well as key collaborations with academia and industry partners.